Tag: antibody-drug conjugate
Companion Diagnostics: Paving the Way for Personalized Medicine
There has been a real revolution in the understanding of molecular biology. This revolution is fueled by the rapid decline in the costs of...
Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
The glycoprotein NMB or gpNMB, a novel transmembrane protein which is overexpressed in 40% to 60% of breast cancers, promotes metastases in animal models...
Consideration for the Safe and Effective Manufacturing of Antibody-drug Conjugates
Antibody drug conjugates are an emerging class of biotherapeutics which require unique supporting infrastructure to meet bio/ pharmaceutical industry standards for safe, effective and reliable manufacturing. These highly potent biopharmaceuticals present a series of unique manufacturing challenges driven by their potency and raw material supply chain. Facility design must take into consideration these manufacturing challenges to insure employee safety and robust process performance. The concepts addressed in this article convey the experience gained by Lonza during our years working with this class of biotherapeutics.
Harnessing the Power of Three: Advancing Antibody-Drug Conjugates from Laboratory to...
Antibody-drug conjugates or ADCs are creating much excitement among life science professionals, medical/clinical research scientists and pharmaceutical specialists. At the same time, oncologists and hematologists are eager to welcome new treatment options in the ongoing war against cancer. This article reviews some of the advances made in the development of ADCs.
Anti-CD22 Monomethyl Auristatin Antibody-drug Conjugate Offers Potential Treatment for Non-Hodgkins Lymphoma
Antibody-drug conjugates (ADCs) are target-specific anticancer agents consisting of cytotoxic drugs covalently linked to a monoclonal antibody. They allow specific targeting of drugs to neoplastic...
Total Antibody Quantification for MMAE-Conjugated Antibody-Drug Conjugates: Impact of Assay Format...
The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody...
The Analytical and Bioanalytical Technologies for Characterizing Antibody-drug Conjugates
Antibody-drug conjugates (ADCs) require multiple assays for analytical and bioanalytical characterization due to their heterogeneous and dynamic nature. These assays can help address questions...
Design and Efficacy of Antibody-drug Conjugates in Oncology
The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody...
